FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Matsuda Masaru
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/3/2020 

3. Issuer Name and Ticker or Trading Symbol

HALOZYME THERAPEUTICS, INC. [HALO]
(Last)        (First)        (Middle)

C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY ROAD
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
SVP, General Counsel /
(Street)

SAN DIEGO, CA 92121      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 4489 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase Common Stock 9/4/2019 (1)9/4/2028 Common Stock 101975 $18.16 D  
Option to Purchase Common Stock 2/12/2020 (1)2/12/2029 Common Stock 31505 $16.65 D  
Restricted Stock Unit Award 9/4/2019 (2) (2)Common Stock 20650  (2)D  
Restricted Stock Unit Award 2/12/2020 (2) (2)Common Stock 16517  (2)D  

Explanation of Responses:
(1) This option vests one-fourth on such date and then vests 1/48th monthly thereafter.
(2) One-fourth of the original grant vests on such date and one-fourth vests annually thereafter. Represents a restricted stock unit award with no exercise price.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Matsuda Masaru
C/O HALOZYME THERAPEUTICS, INC.
11388 SORRENTO VALLEY ROAD
SAN DIEGO, CA 92121


SVP, General Counsel

Signatures
/s/ James R. Oehler as attorney-in-fact for Masaru Matsuda1/6/2020
**Signature of Reporting PersonDate

Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Halozyme Therapeutics Charts.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Halozyme Therapeutics Charts.